SCHEMBL6380230

SCHEMBL6380230

CCCCOc1ccc(C=c2[nH]c(=O)c(=Cc3ccc(OC)cc3)[nH]c2=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SERPINE1 P05121 9/20 0.67
▸ HRH3 Q9Y5N1 1/20 0.53
▸ AHR P35869 1/20 0.51
▸ ALOX5 P09917 2/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ PIM2 Q9P1W9 1/20 0.47
▸ MEN1 O00255 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6380223 1.00 SERPINE1 (0.67) SERPINE1HRH3AHRALOX5PIM1
SCHEMBL8495426 0.96 SERPINE1 (0.62) SERPINE1HRH3AHRALOX5PIM1
SCHEMBL8495431 0.96 SERPINE1 (0.62) SERPINE1HRH3AHRALOX5PIM1
SCHEMBL6380172 0.89 SERPINE1 (0.74) SERPINE1HRH3PIM1PIM2MEN1
SCHEMBL6380170 0.89 SERPINE1 (0.74) SERPINE1HRH3PIM1PIM2MEN1
SCHEMBL14399876 0.88 SERPINE1 (0.55) SERPINE1HRH3AHRALOX5MAPT
SCHEMBL8490817 0.87 SERPINE1 (0.60) SERPINE1HRH3SMN1; SMN2
SCHEMBL8490810 0.87 SERPINE1 (0.60) SERPINE1HRH3SMN1; SMN2
SCHEMBL8496917 0.85 SERPINE1 (0.55) SERPINE1HRH3SMN1; SMN2
SCHEMBL8496911 0.85 SERPINE1 (0.55) SERPINE1HRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0655060-B1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LTD (GB) 1998-01-14 — — EP claimed
EP-0655060-A1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LIMITED (GB) 1995-05-31 — — EP claimed
WO-1994004512-A1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LIMITED (GB) 1994-03-03 — — WO claimed
US-20050249681-A1 Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations BASF AKTIENGESELLSCHAFT (DE) 2005-11-10 — — US disclosed
EP-0655060-B1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LTD (GB) 1998-01-14 — — EP disclosed
US-5700804-A INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITORS XENOVA LIMITED (GB) 1997-12-23 — — US disclosed
EP-0655060-A1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LIMITED (GB) 1995-05-31 — — EP disclosed
WO-1994004512-A1 PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES XENOVA LIMITED (GB) 1994-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050249681-A1 Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations DHPS, MC1R, MITF SERPINE1 1257/4885HRH3 1609/4885AHR 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback